Rznomics Inc.

Rznomics inc. email format

Verified email-pattern data for Rznomics Inc. is currently limited. You can still use the company insights and contact sections below.
Rznomics is developing safe and effective biopharmaceuticals in oncology, degenerative disease, and genetic disease based on RNA platform technology called trans-splicing ribozyme. Acknowledged by bio-focused institutions, Rznomics has raised \23.7 billion from series A& B and recently raised \37.2 billion from series C, resulting in a total of \60.9 billion of fundraising. Also, Rznomics received \8 billion for the new drug development research funding from the government. In 2022 1H, Rznomics’ RZ-001 IND submission for the HCC treatment was approved by MFDS, and the clinical trial for the RZ-001 is currently running. In addition to the RZ-001, Rznomics has competitive and innovative pipelines, such as glioblastoma multiforme, Alzheimer’s disease, genetic ocular disease (retinitis pigmentosa), and circular RNA technology. Rznomics is also actively partnering with global companies to discuss collaboration opportunities in co-research, co-development, and licensing.

Company Details

Employees
13
Founded
-
Address
분당구 판교로 253, 이노밸리c동 801호,korea, Republic Of
Industry
Research Services
Keywords
성남시.
HQ
성남시, 경기도
Looking for a particular Rznomics Inc. employee's phone or email?

Rznomics Inc. Questions

Explore related pages

Related company profiles:

Top Rznomics Inc. Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant